At a glance
ClinicalIndex Comparison RecordN/ACompleted· 142 enrolled
Drug / intervention
99Tc-MDP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Trial of 99Tc-MDP and Fosamax in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis Treated With Supraphysiological Doses of Thyroid Hormone
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine·interventional·Posted Dec 2, 2014·Updated Nov 17, 2021
In Brief
A clinical study evaluating 99Tc-MDP and Fosamax for Differentiated Thyroid Cancer and Osteoporosis. Completed, enrolled 142 participants across 1 site.
Detailed Summary
Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis. Therefore, the investigators try to investigate the effects of 99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDifferentiated Thyroid Cancer, Osteoporosis
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionDec 2019
TodayJul 2026
First PostedDec 2, 2014
Enrollment StartJan 1, 2015
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.6 years ago
Interventions
99Tc-MDPdrug
99Tc-MDP, H20000218
Fosamaxdrug
H20080172